Successful treatment of superior vena cava syndrome with urokinase in an infant with a central venous catheter.
An infant with superior vena cava syndrome due to thrombus formation in the superior vena cava, sourced from a central venous line, was treated with urokinase. It was used in a loading dose of 250,000 units/1.73 m2/15 min, followed by continuous infusion of 125,000 units/1.73 m2/h for three days. After two days of urokinase treatment, the clinical signs of superior vena cava syndrome completely disappeared. No bleeding complication was observed.
Caglar
M K
MK
Department of Pediatrics, University Hospital Nijmegen, The Netherlands.
Tolboom
J
J
D002405:Catheterization, Central Venous / Q000295:instrumentation*; D002408:Catheters, Indwelling / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D010289:Parenteral Nutrition, Total / Q000295:instrumentation; D013479:Superior Vena Cava Syndrome / Q000188:drug therapy*; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
D014568:Urokinase-Type Plasminogen Activator